Literature DB >> 17487226

5-HT 1B receptor-mediated serotoninergic modulation of methylphenidate-induced locomotor activation in rats.

Janusz Borycz1, Agustin Zapata, César Quiroz, Nora D Volkow, Sergi Ferré.   

Abstract

Previous studies have shown that the dopamine (DA) uptake blocker methylphenidate, a psychostimulant widely used for the treatment of attention-deficit hyperactivity disorder (ADHD), prevents the neurotoxic effects of the highly abused DA releaser methamphetamine. However, there is a lack of information about the pharmacological interactions of these two drugs at the behavioral level. When systemically administered within an interval of 2 h, previous administration of methylphenidate (10 mg/kg, intraperitoneal (i.p.)) did not modify locomotor activation induced by methamphetamine. On the other hand, previous administration of methamphetamine (1 mg/kg, i.p.) markedly potentiated methylphenidate-induced motor activation. With in vivo microdialysis experiments, methamphetamine and methylphenidate were found to increase DA extracellular levels in the nucleus accumbens (NAs). Methamphetamine, but not methylphenidate, significantly increased the extracellular levels of serotonin (5-HT) in the NAs. Methamphetamine-induced 5-HT release remained significantly elevated for more than 2 h after its administration, suggesting that the increased 5-HT could be responsible for the potentiation of methylphenidate-induced locomotor activation. In fact, previous administration of the 5-HT uptake blocker fluoxetine (10 mg/kg, i.p.) also potentiated the motor activation induced by methylphenidate. A selective 5-HT 1B receptor antagonist (GR 55562; 1 mg/kg), but not a 5-HT2 receptor antagonist (ritanserin; 2 mg/kg, i.p.), counteracted the effects of methamphetamine and fluoxetine on the motor activation induced by methylphenidate. Furthermore, a 5-HT 1B receptor agonist (CP 94253; 1-10 mg/kg, i.p.) strongly and dose-dependently potentiated methylphenidate-induced locomotor activation. The 5-HT 1B receptor-mediated modulation of methylphenidate-induced locomotor activation in rat could have implications for the treatment of ADHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487226     DOI: 10.1038/sj.npp.1301445

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  24 in total

1.  Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood.

Authors:  Brandon L Warren; Sergio D Iñiguez; Lyonna F Alcantara; Katherine N Wright; Eric M Parise; Sarah K Weakley; Carlos A Bolaños-Guzmán
Journal:  J Neurosci       Date:  2011-07-13       Impact factor: 6.167

Review 2.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

3.  Effects of psychotropic drugs on second messenger signaling and preference for nicotine in juvenile male mice.

Authors:  Lyonna F Alcantara; Brandon L Warren; Eric M Parise; Sergio D Iñiguez; Carlos A Bolaños-Guzmán
Journal:  Psychopharmacology (Berl)       Date:  2014-01-23       Impact factor: 4.530

4.  Methylphenidate modulates dorsal raphe neuronal activity: Behavioral and neuronal recordings from adolescent rats.

Authors:  Natasha Kharas; Holly Whitt; Cruz Reyes-Vasquez; Nachum Dafny
Journal:  Brain Res Bull       Date:  2016-11-23       Impact factor: 4.077

5.  The 5-HT1B serotonin receptor regulates methylphenidate-induced gene expression in the striatum: Differential effects on immediate-early genes.

Authors:  David Alter; Joel A Beverley; Ronak Patel; Carlos A Bolaños-Guzmán; Heinz Steiner
Journal:  J Psychopharmacol       Date:  2017-07-18       Impact factor: 4.153

Review 6.  Association of Serotonin Receptors with Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis.

Authors:  Yu-Wei Hou; Ping Xiong; Xue Gu; Xin Huang; Min Wang; Jing Wu
Journal:  Curr Med Sci       Date:  2018-06-22

7.  Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

Authors:  Z Speiser; T Fine; L Litinetsky; S Eliash; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

8.  Conditioned place preference and locomotor activity in response to methylphenidate, amphetamine and cocaine in mice lacking dopamine D4 receptors.

Authors:  P K Thanos; C Bermeo; M Rubinstein; K L Suchland; G J Wang; D K Grandy; N D Volkow
Journal:  J Psychopharmacol       Date:  2009-03-12       Impact factor: 4.153

9.  Direct and indirect 5-HT receptor agonists produce gender-specific effects on locomotor and vertical activities in C57 BL/6J mice.

Authors:  Bethany R Brookshire; Sara R Jones
Journal:  Pharmacol Biochem Behav       Date:  2009-08-19       Impact factor: 3.533

10.  Critical role of the embryonic mid-hindbrain organizer in the behavioral response to amphetamine and methylphenidate.

Authors:  H Tilleman; O Kofman; L Nashelsky; U Livneh; N Roz; I Sillaber; A Biegon; M Rehavi; C Brodski
Journal:  Neuroscience       Date:  2009-07-24       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.